Roth Capital Reiterates Buy on Zosano Pharma (ZSAN) Following Positive ZP-Glucagon Data

Roth Capital reiterated a Buy rating and $11.00 price target on Zosano Pharma (NASDAQ: ZSAN) following reported positive phase 2 data on the ZP-Glucagon program. The trial compared safety and efficacy of two ZP-Glucagon patches versus two doses of intramuscular injections. There was limited data in the press release, but 100% efficacy appears robust. Further, the company is evaluating a pivotal phase 3 trial for 2016.

Analyst Scott Henry commented, "ZSAN reported phase 2 data on the ZP-Glucagon program to treat hypoglycemia. Although details are limited, all signs point to a robust data set (100% efficacy, moving to phase 3 trials). We reiterate our Buy rating as we find the stock trading at unsustainably low levels."

For an analyst ratings summary and ratings history on Zosano Pharma click here. For more ratings news on Zosano Pharma click here.

Shares of Zosano Pharma closed at $2.79 yesterday.

You May Also Be Interested In

• META to capture largest share of users, SNAP to benefit from ad budget shifts - Canaccord Genuity weighs in on TikTok ban
• Teradyne (TER) PT Raised to $125 at TD Cowen
• Sage Therapeutics (SAGE) PT Lowered to $18 at Truist Securities